A phase 2 study of XL999 administered intravenously to subjects with non-small-cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2015
At a glance
- Drugs XL 999 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Symphony Evolution
- 23 Feb 2010 Actual patient number (9) added as reported by ClinicalTrials.gov.
- 23 Feb 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Feb 2010 Planned end date (1 Jul 2008) added as reported by ClinicalTrials.gov.